Efficacy and toxicity of combined immunochemotherapy in the treatment of patients with bronchogenic carcinoma with PD-L1 receptor expression < 1 % - case report
Abstract
The following case report discusses the benefits and potential risks of one of the most modern treatment modalities available to us in clinical oncology. Immunotherapy targeted at control points of the immune response can achieve a significant and lasting therapeutic response in a relatively high percentage of patients, especially in a double combination.
However, these impressive therapeutic results are not without side effects. The use of a molecule targeting the CTLA-4 receptor is riskier for the development of toxicity and is dose-dependent.
Fewer cases of autoimmune reactions are then observed with the use of anti-PD-1 monoclonal antibodies and even less with the use of anti-PD-LI monoclonal antibodies. As we already know from many clinical studies, autoimmune-related adverse effects of immunotherapy are mostly associated with the therapeutic effect.
The following case study shows exactly this causal evidence.